...
机译:慢性骨髓白血病患者的结果在3和6个月的早期分子响应:通用伊马替尼和GLIVEC的比较分析
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Department of Hematology Haseki Training and Research Hospital;
Department of Hematology Okmeydani Training and Research Hospital;
Department of Hematology Okmeydani Training and Research Hospital;
Department of Hematology Okmeydani Training and Research Hospital;
Department of Hematology Istanbul Training and Research Hospital;
Department of Hematology Istanbul Training and Research Hospital;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
Department of Pathology Cerrahpasa Faculty of Medicine Istanbul University;
Department of Genetics Institute of Experimental Medicine (DETAE) Istanbul University;
Division of Hematology Department of Internal Medicine Cerrahpasa Faculty of Medicine Istanbul;
BCR-ABL1; CML; Generic imatinib; Outcome; Response;
机译:慢性骨髓白血病患者的结果在3和6个月的早期分子响应:通用伊马替尼和GLIVEC的比较分析
机译:分子监测对慢性粒细胞白血病患者伊马替尼(Glivec)的反应:在沙特阿拉伯一家三级护理医院的经验
机译:少量分子反应对第一线伊马替尼的慢性分子慢性骨髓白血病患者中尼洛涅布对高剂量伊替尼与持续标准剂量伊替尼的比较分析
机译:重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
机译:对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
机译:使用通用伊马替尼作为慢性骨髓白血病患者的一线治疗(CML):GIMS(Glivec到iMatinib交换机)的研究
机译:3个月时的初始分子反应可预测伊马替尼耐药或不耐受患者24个月的反应和无事件生存率,其中尼罗替尼治疗慢性期费城染色体阳性慢性粒细胞白血病